Cambridge Investment Research Advisors, Inc. Global Blood Therapeutics, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 17, 2022	BUY	$32.4 - $68.18 $117,126 - $246,470	3,615 New	3,615 $246,000
Q2 2022 Jul 13, 2022	SELL	$22.3 - $37.39 $164,730 - $276,199	-7,387 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$25.68 - $35.59 $23,112 - $32,031	-900 Reduced 10.86%	7,387 $255,000
Q4 2021 Feb 03, 2022	BUY	$24.9 - $40.26 $206,346 - $333,634	8,287 New	8,287 $242,000
Q4 2020 Feb 04, 2021	SELL	$37.65 - $63.77 $231,886 - $392,759	-6,159 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$52.76 - $74.49 $19,521 - $27,561	370 Added 6.39%	6,159 $339,000
Q2 2020 Jul 27, 2020	SELL	$48.73 - $81.82 $31,723 - $53,264	-651 Reduced 10.11%	5,789 $365,000
Q1 2020 May 08, 2020	BUY	$41.72 - $87.2 $32,040 - $66,969	768 Added 13.54%	6,440 $329,000
Q4 2019 Feb 04, 2020	BUY	$45.7 - $81.86 $32,766 - $58,693	717 Added 14.47%	5,672 $450,000
Q3 2019 Nov 06, 2019	BUY	$45.35 - $57.91 $9,070 - $11,582	200 Added 4.21%	4,955 $240,000
Q2 2019 Aug 15, 2019	SELL	$52.6 - $63.29 $72,062 - $86,707	-1,370 Reduced 22.37%	4,755 $0
Q1 2019 May 08, 2019	SELL	$39.99 - $53.48 $8,197 - $10,963	-205 Reduced 3.24%	6,125 $0
Q4 2018 Feb 05, 2019	SELL	$31.54 - $46.67 $16,558 - $24,501	-525 Reduced 7.66%	6,330 $259,000
Q3 2018 Nov 02, 2018	BUY	$38.0 - $51.1 $59,090 - $79,460	1,555 Added 29.34%	6,855 $0
Q2 2018 Aug 10, 2018	BUY	$38.7 - $50.15 $205,110 - $265,795	5,300 New	5,300 $0

Others Institutions Holding GBT

# of Institutions

Shares Held

288K

Call Options Held

Put Options Held

View Full List

About Global Blood Therapeutics, Inc.

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

More about GBT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account